New CEO for HERVOLUTION

J. Robert Coleman has been appointed chief executive officer of HERVOLUTION Therapeutics ApS, a biotechnology company developing cancer immunotherapies targeting human endogenous retroviruses (HERVs) in the dark genome. Dr Coleman has over 12 years’ experience in biotech with a particular focus on driving platform technologies from initial innovation to Phase 3 clinical trials. Heco-founded and was CEO of Codagenix Inc where he raised up to $498 million in financing to support early and late-stage development of viral-based vaccines and therapeutics. Denmark-based HERVOLUTION is expanding into the US with Dr Coleman's appointment.

The company’s pipeline includes therapies that target HERV expression in prostate, pancreatic, breast and other cancers, as well as in senescent cells and degenerative diseases like multiple sclerosis and amyotrophic lateral sclerosis. Dr Coleman has a bachelor of science in cell and molecular biology from Tulane University, a PhD in molecular microbiology from Stony Brook University and an MBA from New York Institute of Technology, all US.

HERVOLUTION announced the appointment on December 19, 2023.